fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 35. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Statex (00591467), Statex (00591475). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Morphine sulfate

Form:

24 of 24 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Morphine Sulfate Injection USP · DIN 02242484 · 2 mg/mL · injection solution Amp

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Morphine Sulfate Injection USP · DIN 02242484 Manufacturer: Sandoz Canada Inc.; listing date 2018-01-31 Health Canada: Marketed since 2005-08-09 · brand MORPHINE SULFATE INJECTION USP · ATC N02AA01 MORPHINE · form Liquid · route Intravenous, Subcutaneous, Intramuscular · ingredients MORPHINE SULFATE 2 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Morphine Sulfate Injection USP: Formulary list price $2.25 per unit (the source does not state the unit; exact figure $2.2510). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242484)

Source record
DIN 02242484: Morphine Sulfate Injection USP Raw flags: sec3=Y Item: 280808150; group id 408; item number 0992; lccId None; manufacturer id SDZ Source form: Inj Sol Amp; strength: 2mg/mL Recorded listing: General benefit Source prices (unrounded): $2.2510; ministry $2.2510 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242484 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66221
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242484
Shortage record checked October 6, 2026

PMS-Morphine Sulfate · DIN 02549794 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
PMS-Morphine Sulfate · DIN 02549794 Manufacturer: Pharmascience Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-07-29 · brand PMS-MORPHINE SULFATE · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 5 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Morphine Sulfate: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0709). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549794)

Source record
DIN 02549794: PMS-Morphine Sulfate Raw flags: sec3=Y Item: 280808047; group id 408; item number 1007; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0709; ministry $0.0709 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549794 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103861
Interchangeable products
Statex · DIN 00594652 · $0.0709
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549794
Shortage record checked October 6, 2026

Statex · DIN 00594652 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Statex · DIN 00594652 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-03-05 · brand STATEX · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 5 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Statex: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0709). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00594652)

Source record
DIN 00594652: Statex Raw flags: sec3=Y Item: 280808047; group id 408; item number 1007; lccId None; manufacturer id KNT Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0709; ministry $0.0709 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00594652 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6755
Interchangeable products
PMS-Morphine Sulfate · DIN 02549794 · $0.0709
Shortage status: resolved shortage (ended May 1, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00594652
Shortage record checked October 6, 2026

M-Eslon · DIN 02019930 · 10 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019930 Manufacturer: Ethypharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-08-22 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 10 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Eslon: Formulary list price $0.34 per unit (the source does not state the unit; exact figure $0.3416). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019930)

Source record
DIN 02019930: M-Eslon Raw flags: sec3=Y Item: 280808068; group id 408; item number 0987; lccId None; manufacturer id ETH Source form: ER Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.3416; ministry $0.3416 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019930 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14543
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019930
Shortage record checked October 6, 2026

Morphine Sulfate · DIN 00392588 · 10 mg/mL · injection solution Amp

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Morphine Sulfate · DIN 00392588 Manufacturer: Sandoz Canada Inc.; listing date 2018-01-31 Health Canada: Marketed since 2005-08-09 · brand MORPHINE SULFATE INJ 10MG/ML USP · ATC N02AA01 MORPHINE · form Solution · route Intravenous, Intramuscular, Subcutaneous · ingredients MORPHINE SULFATE 10 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Morphine Sulfate: Formulary list price $2.39 per unit (the source does not state the unit; exact figure $2.3860). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00392588)

Source record
DIN 00392588: Morphine Sulfate Raw flags: sec3=Y Item: 280808151; group id 408; item number 0993; lccId None; manufacturer id SDZ Source form: Inj Sol Amp; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $2.3860; ministry $2.3860 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00392588 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3043
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00392588
Shortage record checked October 6, 2026

Kadian · DIN 02242163 · 10 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Kadian · DIN 02242163 Manufacturer: BGP Pharma ULC; listing date 2003-01-30 Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 10 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Kadian: Formulary list price $0.48 per unit (the source does not state the unit; exact figure $0.4750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242163)

Source record
DIN 02242163: Kadian Raw flags: sec3=Y Item: 280808125; group id 408; item number 0996; lccId None; manufacturer id BGP Source form: SR Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.4750; ministry $0.4750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242163 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65841
Shortage status: resolved shortage (ended August 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242163
Shortage record checked October 6, 2026

PMS-Morphine Sulfate · DIN 02549808 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
PMS-Morphine Sulfate · DIN 02549808 Manufacturer: Pharmascience Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-07-29 · brand PMS-MORPHINE SULFATE · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 10 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Morphine Sulfate: Formulary list price $0.11 per unit (the source does not state the unit; exact figure $0.1096). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549808)

Source record
DIN 02549808: PMS-Morphine Sulfate Raw flags: sec3=Y Item: 280808048; group id 408; item number 1008; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1096; ministry $0.1096 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549808 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103862
Interchangeable products
Statex · DIN 00594644 · $0.1096
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549808
Shortage record checked October 6, 2026

Statex · DIN 00594644 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Statex · DIN 00594644 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-03-05 · brand STATEX · ATC N02AA01 MORPHINE · form Tablet · route Oral · ingredients MORPHINE SULFATE 10 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Statex: Formulary list price $0.11 per unit (the source does not state the unit; exact figure $0.1096). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00594644)

Source record
DIN 00594644: Statex Raw flags: sec3=Y Item: 280808048; group id 408; item number 1008; lccId None; manufacturer id KNT Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1096; ministry $0.1096 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00594644 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6754
Interchangeable products
PMS-Morphine Sulfate · DIN 02549808 · $0.1096
Shortage status: resolved shortage (ended March 27, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00594644
Shortage record checked October 6, 2026

M-Eslon · DIN 02177749 · 15 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02177749 Manufacturer: Ethypharm Inc.; listing date 1996-12-19 Health Canada: Marketed since 2006-07-17 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Eslon: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3941). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02177749)

Source record
DIN 02177749: M-Eslon Raw flags: sec3=Y Item: 280808086; group id 408; item number 0988; lccId None; manufacturer id ETH Source form: ER Cap; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.3941; ministry $0.3941 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02177749 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18878
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02177749
Shortage record checked October 6, 2026

Morphine Sulfate · DIN 00392561 · 15 mg/mL · injection solution Amp

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Morphine Sulfate · DIN 00392561 Manufacturer: Sandoz Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2005-08-09 · brand MORPHINE SULFATE INJ 15MG/ML USP · ATC N02AA01 MORPHINE · form Solution · route Intramuscular, Intravenous, Subcutaneous · ingredients MORPHINE SULFATE 15 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Morphine Sulfate: Formulary list price $2.09 per unit (the source does not state the unit; exact figure $2.0940). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00392561)

Source record
DIN 00392561: Morphine Sulfate Raw flags: sec3=Y Item: 280808040; group id 408; item number 0994; lccId None; manufacturer id SDZ Source form: Inj Sol Amp; strength: 15mg/mL Recorded listing: General benefit Source prices (unrounded): $2.0940; ministry $2.0940 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00392561 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3042
Interchangeable products
Morphine Sulfate Injection USP · DIN 00850330 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00392561
Shortage record checked October 6, 2026

MS Contin · DIN 02015439 · 15 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
MS Contin · DIN 02015439 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02015439)

Source record
DIN 02015439: MS Contin Raw flags: sec3=Y Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id PFP Source form: SR Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $1.0086; ministry $0.4145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02015439 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14395
Interchangeable products
Sandoz Morphine SR · DIN 02244790 · $0.4145 Teva-Morphine SR · DIN 02302764 · $0.4145
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02015439
Shortage record checked October 6, 2026

Sandoz Morphine SR · DIN 02244790 · 15 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Morphine SR · DIN 02244790 Manufacturer: Sandoz Canada Inc.; listing date 2002-07-29 Health Canada: Marketed since 2010-12-11 · brand SANDOZ MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Morphine SR: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4145). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244790)

Source record
DIN 02244790: Sandoz Morphine SR Raw flags: sec3=Y Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id SDZ Source form: SR Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.4145; ministry $0.4145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244790 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68780
Interchangeable products
MS Contin · DIN 02015439 · $0.4145 Teva-Morphine SR · DIN 02302764 · $0.4145
Shortage status: resolved shortage (ended September 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244790
Shortage record checked October 6, 2026

Teva-Morphine SR · DIN 02302764 · 15 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Morphine SR · DIN 02302764 Manufacturer: Teva Canada Limited; listing date 2009-04-01 Health Canada: Marketed since 2011-06-03 · brand TEVA-MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 15 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Morphine SR: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4145). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302764)

Source record
DIN 02302764: Teva-Morphine SR Raw flags: sec3=Y Item: 280808053; group id 408; item number 1000; lccId None; manufacturer id TEV Source form: SR Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.4145; ministry $0.4145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302764 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78808
Interchangeable products
MS Contin · DIN 02015439 · $0.4145 Sandoz Morphine SR · DIN 02244790 · $0.4145
Shortage status: resolved shortage (ended August 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02302764
Shortage record checked October 6, 2026

Kadian · DIN 02184435 · 20 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Kadian · DIN 02184435 Manufacturer: BGP Pharma ULC; listing date 1997-08-28 Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 20 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Kadian: Formulary list price $0.92 per unit (the source does not state the unit; exact figure $0.9228). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02184435)

Source record
DIN 02184435: Kadian Raw flags: sec3=Y Item: 280808093; group id 408; item number 0997; lccId None; manufacturer id BGP Source form: SR Cap; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.9228; ministry $0.9228 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02184435 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42846
Shortage status: resolved shortage (ended August 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184435
Shortage record checked October 6, 2026

MS-IR · DIN 02014238 · 20 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
MS-IR · DIN 02014238 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1991-12-31 · brand MS.IR · ATC N02AA01 MORPHINE · form Tablet (immediate-release) · route Oral · ingredients MORPHINE SULFATE 20 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

MS-IR: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4702). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02014238)

Source record
DIN 02014238: MS-IR Raw flags: sec3=Y Item: 280808051; group id 408; item number 1005; lccId None; manufacturer id PFP Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.4702; ministry $0.4702 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02014238 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16480
Shortage status: resolved shortage (ended January 23, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014238
Shortage record checked October 6, 2026

M-Eslon · DIN 02019949 · 30 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019949 Manufacturer: Ethypharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-08-07 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Eslon: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019949)

Source record
DIN 02019949: M-Eslon Raw flags: sec3=Y Item: 280808069; group id 408; item number 0989; lccId None; manufacturer id ETH Source form: ER Cap; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.5875; ministry $0.5875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019949 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14502
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019949
Shortage record checked October 6, 2026

MS Contin · DIN 02014297 · 30 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
MS Contin · DIN 02014297 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02014297)

Source record
DIN 02014297: MS Contin Raw flags: sec3=Y Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id PFP Source form: SR Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1.5245; ministry $0.6580 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02014297 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14176
Interchangeable products
Sandoz Morphine SR · DIN 02244791 · $0.6580 Teva-Morphine SR · DIN 02302772 · $0.6580
Shortage status: resolved shortage (ended December 7, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014297
Shortage record checked October 6, 2026

Sandoz Morphine SR · DIN 02244791 · 30 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Morphine SR · DIN 02244791 Manufacturer: Sandoz Canada Inc.; listing date 2002-07-29 Health Canada: Marketed since 2010-12-11 · brand SANDOZ MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Morphine SR: Formulary list price $0.66 per unit (the source does not state the unit; exact figure $0.6580). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244791)

Source record
DIN 02244791: Sandoz Morphine SR Raw flags: sec3=Y Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id SDZ Source form: SR Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.6580; ministry $0.6580 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244791 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68781
Interchangeable products
MS Contin · DIN 02014297 · $0.6580 Teva-Morphine SR · DIN 02302772 · $0.6580
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244791
Shortage record checked October 6, 2026

Teva-Morphine SR · DIN 02302772 · 30 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Morphine SR · DIN 02302772 Manufacturer: Teva Canada Limited; listing date 2009-06-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-MORPHINE SR · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Morphine SR: Formulary list price $0.66 per unit (the source does not state the unit; exact figure $0.6580). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302772)

Source record
DIN 02302772: Teva-Morphine SR Raw flags: sec3=Y Item: 280808054; group id 408; item number 1001; lccId None; manufacturer id TEV Source form: SR Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.6580; ministry $0.6580 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302772 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78809
Interchangeable products
MS Contin · DIN 02014297 · $0.6580 Sandoz Morphine SR · DIN 02244791 · $0.6580
Shortage status: resolved shortage (ended July 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02302772
Shortage record checked October 6, 2026

MS-IR · DIN 02014254 · 30 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
MS-IR · DIN 02014254 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1991-12-31 · brand MS.IR · ATC N02AA01 MORPHINE · form Tablet (immediate-release) · route Oral · ingredients MORPHINE SULFATE 30 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

MS-IR: Formulary list price $0.60 per unit (the source does not state the unit; exact figure $0.6036). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02014254)

Source record
DIN 02014254: MS-IR Raw flags: sec3=Y Item: 280808052; group id 408; item number 1006; lccId None; manufacturer id PFP Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.6036; ministry $0.6036 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02014254 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16481
Shortage status: resolved shortage (ended May 28, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014254
Shortage record checked October 6, 2026

Morphine HP-50 · DIN 00617288 · 50 mg/mL · injection solution-1mL Pk

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Morphine HP-50 · DIN 00617288 Manufacturer: Sandoz Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2005-08-05 · brand MORPHINE HP 50 · ATC N02AA01 MORPHINE · form Solution · route Subcutaneous, Intramuscular, Intravenous · ingredients MORPHINE SULFATE 50 MG/ML · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Morphine HP-50: Formulary list price $6.82 per unit (the source does not state the unit; exact figure $6.8195). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00617288)

Source record
DIN 00617288: Morphine HP-50 Raw flags: sec3=Y Item: 280808041; group id 408; item number 0995; lccId None; manufacturer id SDZ Source form: Inj Sol-1mL Pk; strength: 50mg/mL Recorded listing: General benefit Source prices (unrounded): $6.8195; ministry $6.8195 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00617288 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7421
Shortage status: resolved shortage (ended February 27, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00617288
Shortage record checked October 6, 2026

Kadian · DIN 02184443 · 50 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Kadian · DIN 02184443 Manufacturer: BGP Pharma ULC; listing date 1997-08-28 Health Canada: Marketed since 2016-05-26 · brand KADIAN · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 50 MG · company Bgp pharma ulc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Kadian: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7456). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02184443)

Source record
DIN 02184443: Kadian Raw flags: sec3=Y Item: 280808094; group id 408; item number 0998; lccId None; manufacturer id BGP Source form: SR Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.7456; ministry $1.7456 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02184443 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42847
Shortage status: resolved shortage (ended August 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184443
Shortage record checked October 6, 2026

M-Eslon · DIN 02019957 · 60 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
M-Eslon · DIN 02019957 Manufacturer: Ethypharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-07-31 · brand M-ESLON · ATC N02AA01 MORPHINE · form Capsule (extended-release) · route Oral · ingredients MORPHINE SULFATE 60 MG · company Ethypharm inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Eslon: Formulary list price $1.05 per unit (the source does not state the unit; exact figure $1.0457). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019957)

Source record
DIN 02019957: M-Eslon Raw flags: sec3=Y Item: 280808070; group id 408; item number 0990; lccId None; manufacturer id ETH Source form: ER Cap; strength: 60mg Recorded listing: General benefit Source prices (unrounded): $1.0457; ministry $1.0457 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019957 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14542
Shortage status: resolved shortage (ended March 14, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02019957
Shortage record checked October 6, 2026

MS Contin · DIN 02014300 · 60 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
MS Contin · DIN 02014300 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 60 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02014300)

Source record
DIN 02014300: MS Contin Raw flags: sec3=Y Item: 280808055; group id 408; item number 1002; lccId None; manufacturer id PFP Source form: SR Tab; strength: 60mg Recorded listing: General benefit Source prices (unrounded): $2.6874; ministry $1.2180 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02014300 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14394
Interchangeable products
Sandoz Morphine SR · DIN 02244792 · $1.2180 Teva-Morphine SR · DIN 02302780 · $1.2180
Shortage status: resolved shortage (ended March 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014300
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N02A, N02AA): coverage varies; not interchangeable

  • Hydromorphone (Hydromorph Contin): general benefit, not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Oxycodone (Supeudol): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, not a benefit

4 more in the class list below

Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults Morphine Sulfate Injection USP, administered by slow intravenous injection, is indicated exclusively for the symptomatic relief of moderate to severe pain. Morphine Sulfate Injection USP is not indicated as an as-needed (prn) analgesic. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy. Pediatrics (< 12years of age) The safety and efficacy of morphine sulfate has not been studied in the pediatric population. N Morphine Sulfate Injection USP Page 3 of 33 Therefore the use of Morphine Sulfate Injection USP is not recommended in patients under 12 years of age. https://pdf.hres.ca/dpd_pm/00057801.PDF PM date: July 15, 2020 Source product: MORPHINE SULFATE INJ 15MG/ML USP; DIN 00392561; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Morphine (Doloral 1, Doloral 5 (TEMPORARY BENEFIT))

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For use in a palliative patient requiring oral liquid morphine. Doloral oral liquid products are interim/temporary listing authorized by the Executive Officer as oral liquid morphine products on the formulary were withdrawn from the market by the manufacturer.

Ministry criteria corpus 2025-01-01; page 474

Morphine Brand(s): Doloral 1, Doloral 5 (TEMPORARY BENEFIT) DOSAGE FORM/ STRENGTH: 1 mg/mL oral liquid, 5 mg/mL oral liquid
For use in a palliative patient requiring oral liquid morphine. Doloral oral liquid products are interim/temporary listing authorized by the Executive Officer as oral liquid morphine products on the formulary were withdrawn from the market by the manufacturer.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.